Previous Clinical Trials
We maintain a deep, sustained focus on movement disorders, with a portfolio spanning Parkinson’s disease, Huntington’s disease, essential tremor, dystonia, multiple system atrophy, ataxia and device/DBS research. The table below lists representative protocols with identifiers, sponsors, status, and dates.
Welcome to Inland Northwest Research’s central hub for previous clinical trials.
Note: Enrollment and start-up timelines, as well as details about monitoring capabilities, are available upon request.
| Protocol ID | Protocol Title | Sponsor | Condition Area | Status | Start Date | End Date |
|---|---|---|---|---|---|---|
| TV56286-NDG-20041 | Open-Label Extension, Phase 2 Trial of TEV-56286 (Emrusolmin) in Multiple System Atrophy | Teva Branded Pharmaceutical | Multiple System Atrophy | Enrolling | 9/24/25 | |
| CAP-003-101 | A Phase 1/2 Dose-Escalation Trial of CAP-003 Gene Therapy in PD with GBA1 Mutation (PD-GBA) | Capsida Biotherapeutics, Inc. | Other / Unclassified | Enrolling | 8/4/25 | |
| CVN424-301 | Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in PD Patients with Motor Complications | Cerevance Beta, Inc. | Other / Unclassified | Enrolling | 1/9/25 | |
| DNLI-C-0009 | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in LRRK2-Associated PD | Denali Therapeutics Inc. | Parkinson's Disease | Maintenance | 12/2/24 | |
| P22-487 | Global Real-World Evidence Study on the Long-Term Effectiveness of ABBV-951 in Advanced Parkinson's Disease (ROSSINI) | P22-487 | Parkinson's Disease | Maintenance | 11/22/24 | |
| WE4591 | Frequency of Selected SNPs in Phase with the Mutant and Wild-Type HTT Alleles in Huntington Disease Gene Expansion Carriers | F. Hoffmann-La Roche Ltd | Huntington's Disease | Closed | 11/19/24 | 8/21/25 |
| Lu AF82422 | Randomized, Double-Blind, Placebo-Controlled Trial of Lu AF82422 in Multiple System Atrophy | H. Lundbeck A/S (Lundbeck) | Multiple System Atrophy | Enrolling | 11/7/24 | |
| VENT-02-102 | A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients with Mild to Moderate Parkinson's Disease | Ventus Therapeutics U.S., Inc. | Parkinson's Disease | Maintenance | 8/22/24 | |
| 97039031 | DBS Illumina 3D Study | Boston Scientific Neuromodulation Corporation | DBS / Neuromodulation (Movement) | Maintenance | 5/6/24 | |
| Lu AF28996 | Open-Label Exploratory Study of Lu AF28996 in Parkinson's Disease | H. Lundbeck A/S (Lundbeck) | Parkinson's Disease | Maintenance | 3/8/24 | |
| PD-0060 | A Multicenter Phase 2, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants with Advanced Parkinson's Disease | UCB Biopharma SRL | Parkinson's Disease | Closed | 1/17/24 | 5/28/25 |
| CT 2401 | Double-Blind, Randomized Controlled Trial to Demonstrate Efficacy of Celeste® Specialized Phototherapy in Treating Symptoms of Parkinson's Disease | PhotoPharmics, Inc | Parkinson's Disease | Enrolling | 1/10/24 | |
| TV56286-NDG-20039 | A Phase 2 Study of TEV-56286 for the Treatment of Multiple System Atrophy | Teva Branded Pharmaceutical | Multiple System Atrophy | Enrolling | 12/5/23 | |
| BIA 28-6156-201 | A Phase 2 Study of BIA 28-6156 in PD With a Pathogenic Variant in the GBA1 Gene | BIAL R&D INVESTMENTS, S.A. | Other / Unclassified | Maintenance | 6/13/23 | |
| BN42489 | A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals with Prodromal and Early Manifest Huntington's Disease | F. Hoffmann-La Roche Ltd | Huntington's Disease | Closed | 4/12/23 | 8/19/25 |
| ITI-214-202 | A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson's Disease | Intracellular | Parkinson's Disease | Closed | 3/23/23 | 3/26/25 |
| SNS-PS-002/003 | Non-Invasive Brainstem Modulation for the Treatment of Non-Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial (RCT) and an Open Label Extension (OLE) Study | Scion NeoroStim,LLC | Parkinson's Disease | Closed | 1/23/23 | 2/28/25 |
| 718-CIH-301 | A Phase 3, Multicenter, Open-Label Safety Study to Evaluate the Long-Term Safety and Tolerability of Sage-718 in Participants with Huntington's Disease | Sage Therapeutics | Huntington's Disease | Closed | 12/12/22 | 3/20/25 |
| 283PD302 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BIIB122/DNL151 in PD with Pathogenic LRRK2 Variants | Biogen | Parkinson's Disease | Closed | 11/10/22 | 8/16/23 |
| TAK-341-2001 | A Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, PK/PD of IV TAK-341 in Multiple System Atrophy | Takeda Development Center Americas, Inc. | Multiple System Atrophy | Closed | 11/7/22 | 10/13/25 |
| 324-ETD-303 | An Open-Label Study of the Long-Term Safety and Tolerability of Sage-324 in Participants with Essential Tremor | Sage Therapeutics | Essential Tremor | Closed | 9/23/22 | 9/14/24 |
| 324-ETD-303 (dup) | An Open-Label Study of the Long-Term Safety and Tolerability of Sage-324 in Essential Tremor | Sage Therapeutics | Essential Tremor | Closed | 9/23/22 | 11/14/24 |
| ANVS-22001 | A 6-Month Randomized, Double-Blind, Placebo-Controlled Trial of Buntanetap in Early Parkinson's Disease | Annovis Bio, Inc. | Parkinson's Disease | Closed | 7/19/22 | 4/29/24 |
| NM201 | A Double-Blind, Placebo-Controlled Study in PD Participants Treated with Carbidopa/Levodopa and NE3107 | BioVie Inc. | Other / Unclassified | Closed | 7/14/22 | 4/20/23 |
| 324-ETD-202 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of Sage-324 for the Treatment of Essential Tremor | Sage Therapeutics | Essential Tremor | Closed | 7/12/22 | 7/16/24 |
| H21-Neuro.15A.SR2106 | Patient Experience with ABBV-951 for Treatment of Advanced Parkinson's Disease (aPD) | Abbvie | Parkinson's Disease | Closed | 6/14/22 | 1/18/23 |
| 718-CIH-201 | A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of Sage-718 on Cognitive Function in Participants with Huntington's Disease | Sage Therapeutics | Huntington's Disease | Closed | 4/14/22 | 1/28/25 |
| 283PD201 - LUMA | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of BIIB122 in Parkinson's Disease | Biogen MA Inc | Parkinson's Disease | Maintenance | 3/29/22 | |
| IRL790C005 | A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating Mesdopetam in Patients with Parkinson's Disease | Integrative Research Laboratories AB Sweden | Parkinson's Disease | Closed | 1/17/22 | 2/13/23 |
| ATH-1017-PD-0201 | A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 in PDD or DLB | Athira Pharma Inc. | Other / Unclassified | Closed | 12/20/21 | 5/31/23 |
| PRAX-944-222 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Trial of PRAX-944 in Adults with Essential Tremor | Praxis Precision Medicines | Essential Tremor | Closed | 12/15/21 | 7/31/23 |
| PRAX 944-221 | A Phase 2 Clinical Trial Evaluating PRAX-944 in Adults with Essential Tremor (Part B) | Praxis | Essential Tremor | Closed | 11/16/21 | 6/22/22 |
| CVL-751-PD-004 | 58-Week Open-Label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial) | Cerevel Therapeutics, LLC | Parkinson's Disease | Closed | 9/8/21 | 4/24/23 |
| NYX-458-2006 | A Study to Evaluate NYX-458 in Subjects With MCI or Mild Dementia Associated With Parkinson's Disease, or Prodromal or Manifest Lewy Body Dementia | Aptinyx | Parkinson's Disease | Closed | 8/19/21 | 1/24/23 |
| PD-0053 | A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants with Early Parkinson's Disease | UCB Biopharma SRL | Parkinson's Disease | Closed | 6/8/21 | 6/15/23 |
| PDGENE-PF | Parkinson's Foundation PD GENEration Genetic Registry (PDGENE-PF) | Parkinson's Foundation | Parkinson's Disease | Enrolling | 3/29/21 | |
| BN42358 (PADOVA) | A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease | F. Hoffmann-La Roche Ltd | Parkinson's Disease | Maintenance | 3/16/21 | |
| M602011069 | Randomized, Double-Blind, Placebo-Controlled Trial with OLE to Investigate NT 201 in Treatment of Essential Tremor of the Upper Limb | Merz | Essential Tremor | Closed | 2/10/21 | 2/16/24 |
| TAK-071-2002 | A Randomized, Double-Blind, Placebo-Controlled, 2 Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls | Takeda Development Center Americas, Inc. | Parkinson's Disease | Closed | 1/25/21 | 3/23/23 |
| TAK-071-2002 (dup) | A Randomized, Double-Blind, Placebo-Controlled, 2 Period Crossover, Phase 2 Study to Evaluate TAK-071 in PD Patients With Cognitive Impairment and Elevated Risk of Falls | Takeda | Other / Unclassified | Closed | 1/25/21 | 3/15/23 |
| OBS16136-PD-FIDI | Validation Study of the PD-FIDI Digital Instrument in Patients with Parkinson's Disease | Sanofi Genzyme Corp. | Parkinson's Disease | Closed | 1/12/21 | 4/14/23 |
| M20-098 | Open-Label Extension of Studies M15-736 and M20-339 Evaluating the Safety and Tolerability of ABBV-951 | Abbvie | Other / Unclassified | Maintenance | 12/10/20 | |
| CVL-751-PD-001 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 Trial) | Cerevel Therapeutics, LLC | Parkinson's Disease | Closed | 8/27/20 | 1/31/23 |
| CVL-751-PD-003 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults with Motor Fluctuations (TEMPO-3 Trial) | Cerevel Therapeutics, LLC | Parkinson's Disease | Closed | 8/27/20 | 2/1/23 |
| D6310C00002 | A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects with Parkinson's Disease |